BSE Live
Oct 01, 16:01Prev. Close
5687.50
Open Price
5687.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 01, 15:59Prev. Close
5689.50
Open Price
5692.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
5710.00 (28)
Profit & Loss account of Divis Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 5,207.32 | 4,737.22 | 3,753.19 | 4,054.74 | 3,742.48 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 21.29 | 41.93 | 28.52 | |
Revenue From Operations [Net] | 5,207.32 | 4,737.22 | 3,731.90 | 4,012.81 | 3,713.96 | |
Total Operating Revenues | 5,310.57 | 4,879.66 | 3,815.94 | 4,023.85 | 3,721.33 | |
Other Income | 189.86 | 156.58 | 112.48 | 75.94 | 94.40 | |
Total Revenue | 5,500.43 | 5,036.24 | 3,928.42 | 4,099.79 | 3,815.73 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 2,182.66 | 2,082.05 | 1,524.28 | 1,563.19 | 1,472.43 | |
Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | -94.10 | -244.22 | -19.38 | -21.61 | 23.27 | |
Employee Benefit Expenses | 608.36 | 530.72 | 446.27 | 490.33 | 357.36 | |
Finance Costs | 6.06 | 3.50 | 1.33 | 2.25 | 2.32 | |
Depreciation And Amortisation Expenses | 185.95 | 168.81 | 142.42 | 123.26 | 118.10 | |
Other Expenses | 798.21 | 662.15 | 614.14 | 554.14 | 470.40 | |
Total Expenses | 3,687.14 | 3,203.01 | 2,709.06 | 2,711.56 | 2,443.89 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 1,813.29 | 1,833.23 | 1,219.36 | 1,388.23 | 1,371.84 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 1,813.29 | 1,833.23 | 1,219.36 | 1,388.23 | 1,371.84 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 387.79 | 472.45 | 287.13 | 285.23 | 283.00 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 36.12 | |
Deferred Tax | 52.79 | 28.13 | 62.65 | 49.73 | 16.75 | |
Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.52 | |
Total Tax Expenses | 440.58 | 500.58 | 349.78 | 334.96 | 264.14 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 1,372.71 | 1,332.65 | 869.58 | 1,053.27 | 1,107.69 | |
Profit/Loss From Continuing Operations | 1,372.71 | 1,332.65 | 869.58 | 1,053.27 | 1,107.69 | |
Profit/Loss For The Period | 1,372.71 | 1,332.65 | 869.58 | 1,053.27 | 1,107.69 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 51.71 | 50.20 | 32.76 | 39.68 | 41.73 | |
Diluted EPS (Rs.) | 51.71 | 50.20 | 32.76 | 39.68 | 41.73 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 803.37 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 669.06 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 1.90 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 17.09 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 849.50 | 265.47 | 265.47 | 0.00 | 265.47 | |
Tax On Dividend | 174.62 | 54.57 | 54.04 | 0.00 | 54.04 | |
Equity Dividend Rate (%) | 800.00 | 800.00 | 500.00 | 500.00 | 500.00 |
10.09.2025
Reduce Divis Laboratories; target of Rs 5400: Geojit Financial Services
07.08.2025
Accumulate Divis Laboratories; target of Rs 6550: Prabhudas Lilladher
07.08.2025
Divis Labs Standalone June 2025 Net Sales at Rs 2,357.00 crore, up 14.25% Y-o-Y
23.05.2025
Accumulate Divis Laboratories; target of Rs 7518: Deven Choksey
07.08.2025
Divis Labs Standalone June 2025 Net Sales at Rs 2,357.00 crore, up 14.25% Y-o-Y
19.05.2025
Divis Labs Consolidated March 2025 Net Sales at Rs 2,585.00 crore, up 12.24% Y-o-Y
19.05.2025
Divis Labs Standalone March 2025 Net Sales at Rs 2,536.00 crore, up 12.26% Y-o-Y
03.02.2025
Divis Labs Consolidated December 2024 Net Sales at Rs 2,319.00 crore, up 25.01% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill